U.S. SECURITIES AND ECHANGE COMMISSION
Washington, D.C. 20549
Form 10-QSB
(Mark One)
[X] Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934 for the quarterly period ended September 30, 2000.
[] Transition report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934 for the Transition period from ____ to ____.
Commission File NO. 0-26557
Stemcell Global Research, Inc.
(Exact name of small business issuer as specified in its charter)
Nevada 88-0407473
(State or other jurisdiction (I.R.S Identification No.)
of incorporation or organization)
9978 Washington Street, Camp Dennison, Ohio 45111
(Address of principal executive offices)
Issuer's telephone no. (513) 831-8007
Check whether the issuer:
(1) filed all reports required to be filed by Section 13 or 15(d) of the
Exchange Act during the past 12 months (or for such shorter period
that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days
X Yes No
As of September 30, 2000, there were 1,924,350 shares outstanding of issuer's
common stock.
PART I. FINANCIAL INFORMATION.
Item 1. Financial Statements
The information required by this item is attached as an exhibit hereto.
Item 2. Management's Discussion and Analysis or Plant of Operation.
The information required by this Item is attached as an
Exhibit hereto.
Signatures
In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Date: November 15, 2000
------------
By: /s/ Dr. Garrell Noah
--------------------
Dr. Garrell Noah, Chairman of the Board, President and Chief Executive
Officer
----------------------------------------------------------------------
By: /s/ David Leytze
--------------------
David Leytze, Director, Vice President, CFO, Secretary/Treasurer
----------------------------------------------------------------
